Abstract: A filtration membrane comprising cellulose fibres, the membrane having a pore size distribution such that the modal pore diameter is between 10 nm and 25 nm and/or wherein less than 5% of the pore volume comprises pores of greater than 40 nm and having a total porosity greater than 30%.

Abstract: The present invention provides method of removing particles from a feed fluid, the method comprising: passing the fluid through a first filtration medium having a thickness of from 5 to 20 ?m, wherein passing the feed fluid through the first filtration medium provides a particle removal probability log10 reduction value (LRV) of greater than or equal to 1 for particles having a diameter of from about 10 to about 40 nm and a particle removal probability log10 reduction value (LRV) of greater than or equal to 3 for particles greater than about 40 nm in diameter; and passing the fluid through a second filtration medium having a thickness of from 20 to 70 ?m (e.g.

Abstract: There is provided a pharmaceutical composition comprising cellulose obtained from algae, or a derivative of said cellulose, and an active pharmaceutical ingredient (e.g. from Type 2 and 4 BCS class), wherein the active pharmaceutical ingredient is in a predominantly amorphous form. Compositions of the invention find particularly utility as formulations comprising BCS Type 2 and 4 drugs, including NSAIDs or other drugs, that may be employed in the treatment of migraine or dysmenorrhea, as well as formulations comprising other poorly soluble active ingredients where rapid release in vivo is advantageous.

Abstract: A filtration membrane comprising cellulose fibres, the membrane having a pore size distribution such that the modal pore diameter is between 10 nm and 25 nm and/or wherein less than 5% of the pore volume comprises pores of greater than 40 nm and having a total porosity greater than 30%.

Abstract: An X-ray amorphous magnesium carbonate is disclosed that is characterized by a cumulative pore volume of pores with a diameter smaller than 10 nm of at least 0.018 cm3/g, and a specific surface areas of at least 60 m2/g. The X-ray amorphous magnesium carbonate is produced by reacting an inorganic magnesium compound with alcohol in a CO2 atmosphere. The X-ray amorphous magnesium carbonate can be a powder or a pellet and acts as a desiccant in, for example, production of food, chemicals or pharmaceuticals.

Abstract: An X-ray amorphous magnesium carbonate is disclosed that is characterized by a cumulative pore volume of pores with a diameter smaller than 10 nm of at least 0.018 cm3/g, and a specific surface areas of at least 60 m2/g. The X-ray amorphous magnesium carbonate is produced by reacting an inorganic magnesium compound with alcohol in a CO2 atmosphere. The X-ray amorphous magnesium carbonate can be a powder or a pellet and acts as a desiccant in, for example, production of food, chemicals or pharmaceuticals.

Abstract: An X-ray amorphous magnesium carbonate is disclosed that is characterized by a cumulative pore volume of pores with a diameter smaller than 10 nm of at least 0.018 cm3/g, and a specific surface areas of at least 60 m2/g. The X-ray amorphous magnesium carbonate is produced by reacting an inorganic magnesium compound with alcohol in a CO2 atmosphere. The X-ray amorphous magnesium carbonate can be a powder or a pellet and acts as a desiccant in, for example, production of food, chemicals or pharmaceuticals.

Abstract: There is provided a pharmaceutical composition comprising cellulose obtained from algae, or a derivative of said cellulose, and an active pharmaceutical ingredient (e.g. from Type 2 and 4 BCS class), wherein the active pharmaceutical ingredient is in a predominantly amorphous form. Compositions of the invention find particularly utility as formulations comprising BCS Type 2 and 4 drugs, including NSAIDs or other drugs, that may be employed in the treatment of migraine or dysmenorrhea, as well as formulations comprising other poorly soluble active ingredients where rapid release in vivo is advantageous.

Abstract: A filtration membrane comprising cellulose fibres, the membrane having a pore size distribution such that the modal pore diameter is between 10 nm and 25 nm and/or wherein less than 5% of the pore volume comprises pores of greater than 40 nm and having a total porosity greater than 30%.

Abstract: An X-ray amorphous magnesium carbonate is disclosed that is characterized by a cumulative pore volume of pores with a diameter smaller than 10 nm of at least 0.018 cm3/g, and a specific surface areas of at least 60 m2/g. The X-ray amorphous magnesium carbonate is produced by reacting an inorganic magnesium compound with alcohol in a CO2 atmosphere. The X-ray amorphous magnesium carbonate can be a powder or a pellet and acts as a desiccant in, for example, production of food, chemicals or pharmaceuticals.

Abstract: An X-ray amorphous magnesium carbonate is disclosed that is characterized by a cumulative pore volume of pores with a diameter smaller than 10 nm of at least 0.018 cm3/g, and a specific surface areas of at least 60 m2/g. The X-ray amorphous magnesium carbonate is produced by reacting an inorganic magnesium compound with alcohol in a CO2 atmosphere. The X-ray amorphous magnesium carbonate can be a powder or a pellet and acts as a desiccant in, for example, production of food, chemicals or pharmaceuticals.

Abstract: An X-ray amorphous magnesium carbonate is disclosed that is characterized by a cumulative pore volume of pores with a diameter smaller than 10 nm of at least 0.018 cm3/g, and a specific surface areas of at least 60 m2/g. The X-ray amorphous magnesium carbonate is produced by reacting an inorganic magnesium compound with alcohol in a CO2 atmosphere. The X-ray amorphous magnesium carbonate can be a powder or a pellet and acts as a desiccant in, for example, production of food, chemicals or pharmaceuticals.

Abstract: A cryogel-forming vinyl alcohol co-polymer is operable to form a cryogel, i.e., a hydrogel formed by crytropic gelation, in an aqueous solution at a concentration of less than about 10% by weight, in the absence of a chemical cross-linking agent and in the absence of an emulsifier. In one embodiment, a vinyl alcohol co-polymer cryogel comprises at least about 75% by weight water and a vinyl alcohol co-polymer, wherein the vinyl alcohol co-polymer is operable to form a cryogel in an aqueous solution at a concentration of less than about 10% by weight, in the absence of a chemical cross-linking agent and in the absence of an emulsifier.

Abstract: A composite material in the form of a continuous structure comprises an intrinsically conducting polymer (ICP) layer coated on a substrate, the composite material having a surface area of at least 0.1 m2/g, at least 1 m2/g, or at least 5 m2/g. Methods of manufacturing the composite material comprise coating the substrate with a layer of the intrinsically conducting polymer. Electrochemical or electrical devices comprise at least one component formed of the composite material.

Abstract: The invention relates to dispersible cellulose powder compositions comprising non-seed cellulose powder derived from algae, fungi or tunicates, which compositions are useful in a variety of products such as food products, pharmaceuticals, cosmetics, paints, biocompatible materials for artificial tissue engineering and implantable biomaterials and relates to methods for preparing non-seed cellulose powder compositions.

Abstract: A cryogel-forming vinyl alcohol co-polymer is operable to form a cryogel, i.e., a hydrogel formed by crytropic gelation, in an aqueous solution at a concentration of less than about 10% by weight, in the absence of a chemical cross-linking agent and in the absence of an emulsifier. In one embodiment, a vinyl alcohol co-polymer cryogel comprises at least about 75% by weight water and a vinyl alcohol co-polymer, wherein the vinyl alcohol co-polymer is operable to form a cryogel in an aqueous solution at a concentration of less than about 10% by weight, in the absence of a chemical cross-linking agent and in the absence of an emulsifier.

Abstract: A composite material in the form of a continuous structure comprises an intrinsically conducting polymer (ICP) layer coated on a substrate, the composite material having a surface area of at least 0.1 m2/g, at least 1 m2/g, or at least 5 m2/g. Methods of manufacturing the composite material comprise coating the substrate with a layer of the intrinsically conducting polymer. Electrochemical or electrical devices comprise at least one component formed of the composite material.

Abstract: The invention relates to dispersible cellulose powder compositions comprising non-seed cellulose powder derived from algae, fungi or tunicates, which compositions are useful in a variety of products such as food products, pharmaceuticals, cosmetics, paints, biocompatible materials for artificial tissue engineering and implantable biomaterials and relates to methods for preparing non-seed cellulose powder compositions.

Abstract: A pharmaceutical composition comprises a pharmaceutically effective amount of an active ingredient and low crystallinity cellulose having a crystallinity index of less than about 75% as measured by X-ray diffraction. The compositions advantageously may be provided in tablet form or granulate form and provide good stability against moisture degradation.

Abstract: Nicotine-containing pharmaceutical compositions wherein nicotine is absorbed into and/or adsorbed onto cellulose of non-seed organism origin, especially cellulose from algae, bacteria and/or fungi.